Showing 1407 results
-
Press release /Approval for moderate to severe pediatric patients six years and older is based on pivotal trial data showing Cosentyx demonstrated superior improvements of skin symptoms compared to placebo1…
-
Press release /Two pivotal Phase III studies did not show additional improvement in best corrected visual acuity (BCVA) for pegpleranib and Lucentis (ranibizumab) combination treatment over standard of care…
-
Media Library /
-
Press release /After 5 years, Kisqali® plus endocrine therapy consistently shows significant and clinically meaningful benefit in invasive disease-free survival1 Kisqali remains the only CDK4/6 inhibitor…
-
Press release /The three-year relapse-free survival (RFS) rate for patients treated with the combination was 58%, compared to 39% with placebo[1] Consistent improvement in RFS observed across all pre-specified…
-
Press release /Kisqali is the first and only CDK4/6 inhibitor to demonstrate a consistent, clinically meaningful benefit across a broad population of patients with HR+/HER2- early breast cancer, regardless of…
-
Press release /Novartis enters into an exclusive option agreement with Ionis and Akcea to license two investigational treatments expected to significantly reduce cardiovascular risk in patients living with…
-
Press release /Der Wirkstoff führt zu rascher Parasitenfreiheit auch bei resistenten Erregerstämmen, blockiert die Übertragung der Erreger und könnte damit eine Wende im Kampf gegen Malaria herbeiführen.…
-
Press release /Coartem® Dispersible*, the first WHO prequalified[1] pediatric antimalarial treatment, has become the standard of care in over 30 malaria-endemic countries Since 2009, Novartis has supplied 300…
-
Press release /WHO prequalified Coartem® 80/480mg is the first and only high strength malaria treatment available for donor-funded public sector procurement Coartem® 80/480mg reduces the pill burden for…